<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656821</url>
  </required_header>
  <id_info>
    <org_study_id>32720/11/18</org_study_id>
    <nct_id>NCT04656821</nct_id>
  </id_info>
  <brief_title>Erector Spinae Block Versus Thoracic Paravertebral Block for Acute Thoracic Herpes Zoster</brief_title>
  <official_title>Ultrasound Guided Erector Spinae Block Versus Ultrasound Guided Thoracic Paravertebral Block for Pain Relief in Patients With Acute Thoracic Herpes Zoster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to study and compare the efficacy and safety of single injection&#xD;
      erector spinae plane block and thoracic paravertebral block in prevention of post herpetic&#xD;
      neuralgia in patients with acute thoracic herpes zoster.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2020</start_date>
  <completion_date type="Anticipated">June 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of post herpetic neuralgia (PHN)</measure>
    <time_frame>3 months</time_frame>
    <description>Persistent herpetic pain after 3 months will reported as post herpetic neuralgia (PHN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Visual Analog Scale (VAS) at baseline, 3, 4, 12, 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of rescue analgesia</measure>
    <time_frame>6 months</time_frame>
    <description>Rescue analgesia in the form of Acetaminophen in a dose of 1,000 mg will be given if Visual Analog Scale (VAS) â‰¥4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The times of complete resolution of pain</measure>
    <time_frame>3 months</time_frame>
    <description>The times of complete resolution of pain (from the date of block until complete disappearance of herpetic pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects and complications</measure>
    <time_frame>1 day</time_frame>
    <description>Hypotension&#xD;
Pneumothorax&#xD;
Local anesthetic toxicity&#xD;
Respiratory depression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Thoracic Herpes Zoster</condition>
  <condition>Erector Spinae Plane Block</condition>
  <condition>Thoracic Paravertebral Block</condition>
  <condition>Pain Relief</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erector Spinae Block (ESB) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Paravertebral Block group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Rx</intervention_name>
    <description>Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector Spinae Block</intervention_name>
    <description>Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.</description>
    <arm_group_label>Erector Spinae Block (ESB) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracic Paravertebral Block</intervention_name>
    <description>Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography</description>
    <arm_group_label>Thoracic Paravertebral Block group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 50 years of age&#xD;
&#xD;
          -  Chest wall herpetic eruption of less than one week&#xD;
&#xD;
          -  Moderate or severe pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Eruption more than one week duration&#xD;
&#xD;
          -  Patients who will not receive appropriate anti-viral therapy&#xD;
&#xD;
          -  Patients with mild pain&#xD;
&#xD;
          -  Infection at the site of injection&#xD;
&#xD;
          -  Patients with a history of renal, hepatic diseases, coagulopathy, steroid therapy,&#xD;
             malignancies.&#xD;
&#xD;
          -  Patient taking chemotherapy and/or radiotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Esraa Hassan Abdelwahab, MSc</last_name>
    <phone>+201010473318</phone>
    <email>esraa.hassan@med.tanta.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta University Hospitals</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esraa Hassan Abdelwahab, MSc</last_name>
      <phone>+201010473318</phone>
      <email>esraa.hassan@med.tanta.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Esraa Hassan Abdelwahab</investigator_full_name>
    <investigator_title>Assistant lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be available upon a reasonable request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

